Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 17/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 17/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 15/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 15/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 14/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16174441 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL11889584 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL22233131 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL18980660 | 0.88 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL22235842 | 0.88 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL28644843 | 0.88 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL11889255 | 0.85 | EPHX1 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL11889257 | 0.85 | EPHX1 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25263000 | 0.81 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL477253 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179397-B2 | Imidazopyrimidine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3860717-A1 | IMIDOZOPYRIMIDINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20200108071-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-04-09 | — | — | US | disclosed |
| WO-2020072656-A1 | IMIDOZOPYRIMIDINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| EP-2481739-B1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO LTD (CN) | 2016-12-14 | — | — | EP | disclosed |
| EP-2481739-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200108071-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | DPYD, KRAS, ABL1 | CHRNB2 4857/4885CHRNA4 4819/4885CHRNB4 4861/4885 |
| US-11179397-B2 | Imidazopyrimidine derivatives | DPYD, KRAS, ABL1 | CHRNB2 4857/4885CHRNA4 4819/4885CHRNB4 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.